To investigate if topography-guided laser in situ keratomileusis (LASIK) depending on the topographic astigmatism which is measured using the Topolyzer leads to a better refractive outcome when compared to treatment of the manifest refractive astigmatism in cases of myopic astigmatism. This was a prospective non-masked, randomized study (block randomization) of postoperative vision and refraction of patients with myopic astigmatism that had LASIK using Contoura vision software. They were divided into three groups according to the treatment strategy, treating the manifest astigmatism in one group, the topographic astigmatism with compensation for the spherical power in the second group and treating the topographic astigmatism without changing the spherical power in the third group. It was conducted at Kasr Alainy Hospital and Dar Eloyon Hospital. The postoperative uncorrected distant visual acuity (UDVA) in each group separately was better than the preoperative corrected distant visual acuity (CDVA) (58% (n=35) had UDVA better than 20/20 and gained 1 line or more); however, eyes treated with the topographic astigmatism without changing the spherical power showed the statistically best results (75% (n=15) had UDVA better than 20/20). The residual anterior corneal astigmatism was lower in this group (the mean 0.47 vs 0.95 and 0.59). No significant difference was noted in the residual refractive astigmatism, but it was also the least in that group. Topography-guided LASIK is a safe and effective ablation profile for treatment of myopic astigmatism. Treating according to the topographic astigmatism shows the best outcome as regards the vision and residual astigmatism.Topography-guided LASIK is a safe and effective ablation profile for treatment of myopic astigmatism. Treating according to the topographic astigmatism shows the best outcome as regards the vision and residual astigmatism. To evaluate the difference between the preoperative marking methods for toric intraocular lens (IOL) implantations using an image-guided system (IGS) and the manual marking method in the same eye. In this retrospective case series, 82 patients (101 eyes) who underwent cataract surgery using both manual and IGS (VERION, Alcon Laboratories) marking were enrolled. First, preoperative reference marks were placed at 6 o'clock and 3 or 9 o'clock position under slit-lamp biomicroscope in the outpatient department using the manual method. Using the reference unit of IGS, the ocular surface data were captured and overlaid. The difference was then measured (preoperative axis misalignment). In the operating room, the orientation of the steep meridian of the manual method was determined based on this reference mark under the surgical microscope. Just before surgery, the digital degree gauge of IGS was overlaid on the ocular surface, and the difference was then measured (total axis misalignment). We calculated the intraoperative axis misalignment by subtracting preoperative axis misalignment from the total axis misalignment. Mean absolute preoperative, intraoperative, and total axis misalignment values were 3.87±3.95 degrees, 5.46±4.42 degrees, and 4.98±4.49 degrees, respectively. In preoperative, intraoperative, and total misalignment, the ratios of 10 degrees or greater were 10 (14.7%), 12 (17.6%), and 20 (19.8%) eyes, respectively. The manual method that determines the fixed position of the toric intraocular lens (IOL) may cause large misalignment compared with the IGS, suggesting that using manual method could sometimes result in a large misalignment of toric IOL implantation.The manual method that determines the fixed position of the toric intraocular lens (IOL) may cause large misalignment compared with the IGS, suggesting that using manual method could sometimes result in a large misalignment of toric IOL implantation. To study preoperative and postoperative optical coherence tomography features and the outcomes of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling for full-thickness macular holes (MHs) associated with proliferative diabetic retinopathy. The data from 14 eyes of 11 patients with full-thickness macular holes and active diabetic fibrovascular proliferation (FVP) with/without tractional retinal detachment who underwent pars plana vitrectomy and standard ILM peeling at Zarifa Aliyeva National Ophthalmology Centre in Baku were analysed. Bilateral surgery for diabetic MHs was performed in 27.3% of patients. The minimum follow-up duration was 6 months. All eyes (100%) achieved type 1 macular hole closure, with residual macular subretinal fluid (SRF) present in 13 cases after surgery (92.9%). The SRF resolved gradually without any interventions. The incidence of SRF was 92.9% at 1 month, 85.7% at 3 months, 50% at 6 months, and 14.3% at 9 months (Cochran's Q test, χ2 (4) =37.44, p<0.0iabetic tractional retinal detachment, and it usually resorbs gradually without any interventions.Over the last decade, biomarkers have significantly improved our understanding of the pathophysiology of Alzheimer disease (AD) and provided valuable tools to examine different disease mechanisms and their progression over time. While several markers of amyloid, tau, neuronal, synaptic, and axonal injury, inflammation, and immune dysregulation in AD have been identified, there is a relative paucity of biomarkers which reflect other disease mechanisms such as oxidative stress, mitochondrial injury, vascular or endothelial injury, and calcium-mediated excitotoxicity. Importantly, there is an urgent need to standardize methods for biomarker assessments across different centers, and to identify dynamic biomarkers which can monitor disease progression over time and/or response to potential disease-modifying treatments. find more The updated research framework for AD, proposed by the National Institute of Aging- Alzheimer's Association (NIA-AA) Work Group, emphasizes the importance of incorporating biomarkers in AD research and defines AD as a biological construct consisting of amyloid, tau, and neurodegeneration which spans pre-symptomatic and symptomatic stages. As results of clinical trials of AD therapeutics have been disappointing, it has become increasingly clear that the success of future AD trials will require the incorporation of biomarkers in participant selection, prognostication, monitoring disease progression, and assessing response to treatments. We here review the current state of fluid AD biomarkers, and discuss the advantages and limitations of the updated NIA-AA research framework. Importantly, the integration of biomarker data with clinical, cognitive, and imaging domains through a systems biology approach will be essential to adequately capture the molecular, genetic, and pathological heterogeneity of AD and its spatiotemporal evolution over time.